What happened Shares of Moderna (NASDAQ: MRNA) climbed 3.6% on Thursday after the drugmaker announced the completion of enrollment for its COVID-19 vaccine study. So what Moderna has enrolled 30,000 people for the phase 3 trial for its coronavirus vaccine candidate, mRNA-1273. The biotech noted that 42% of the participants are from groups deemed to be at high risk of severe COVID-19 disease, including more than 7,000 Americans over the age of 65 and 5,000 people who are younger but have chronic diseases, such as severe obesity and diabetes. Moderna's stock rallied on Thursday as investors applauded its vaccine testing progress. Image source: Getty Images. Importantly, Moderna also said that 37% of study participants are minorities, which the company believes helps to represent the broad diversity of the U.S. population. Now what Over 25,000 participants have already received their second dose of the experimental vaccine. Moderna said it will decide whether to ask the Food and Drug Administration for emergency use authorization after it collects two months of safety data on roughly half of the study's participants. Moderna is competing with the likes of Pfizer, AstraZeneca, Johnson & Johnson, and a host of other organizations in the race to find a safe and effective COVID-19 vaccine. Being first to market would give the winner advantages in terms of initial sales and development funding, and investors understandably cheered Moderna's potential progress in this regard. 10 stocks we like better than Moderna INCWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna INC wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of October 20, 2020 Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.Source